INTRODUCTION
Obesity is medical condition of human in which execs body fat store in body to extant that it may pose bad effect on human health [1] . Person with Body mass index which is the ratio of person's weight to the square of his/her height, is over 30 kg/m 2 is considered obese generally people with body mass index between 25-30 kg/m 2 defined as overweight [1] . Obesity in human increases the tendency of various diseases especially heart decease, diabetes type 2, obstructive sleep apnea, certain class of cancer, and osteoarthritis. [2] Obesity is combination of excessive food in regular intake, no any physical activity and genetic susceptibility [1] [3] .some cases observed due to the mental illness, genes, endocrine disorders [4] . Obese people require more energy to maintain increased body mass as compare to other peoples. [5] [6] Obesity must be preventable through social change and personal choice. [1] Change in regular diet and exercise is main treatment for obesity. [2] Reducing high sugar and fat containing food, and increasing intake of fiber in regular diet, quality of diet can increases. [1] combination of medicinal treatment and suitable diet is also taken to reduce appetite or decrease fat absorption. [7] 2. ORLISTAT Orlistat is drug which is used for the treatment of obesity and it sold in market as a prescription drug with tread name Xenical by in most of nations, also sold in UK with name alli by GlaxoSmithKline. It act as lipase inhibitor and prevents reducing of fate from human diet thus calorie intake is reduces [8] . Orlistat is derivative of lipstatin with high potency of pancreatic lipases which is isolated from bacterium Streptomycestoxytricini [9] . Due to its simplicity and stability from others lipstatin, it was chosen as an anti obesity drug. [10] Orlistat is useful for the various treatments such as weight loss [11] and as a secondary effect it reduces the blood pressure. Its preventive effect for the type 2 diabetes is also reported [12] .
Each drug has positive and negative effects too. Orlistat is notorious due to its gastrointestinal side effect which can include steatorrhea, which are decreases with time and reported as adverse effect of drug. [12] 
LITERATURE REVIEW
The literature reviews regarding Orlistat suggested that various analytical methods are reported for stability of Orlistat in pharmaceutical formulations and in various biological fluids by using various analytical techniques as UV, HPLC, UPLC, and TLC method. The literature reviews regarding these methods are as under.
EXPERIMENTAL

Chemicals and Reagents
An active pharmaceutical ingredient (API) working standard of Orlistat was gifted by Dr. Y. T. Naliapara, Assistant Professor, Department of Chemistry, Saurashtra University, Rajkot.
HPLC grade Dichloro methane (MDC), ethyl acetate, glacial acetic acid and n-hexane were procured from Merck India Limited, Mumbai, India. High purity deionised water was prepared using Milli-Q (Millipore, Milford, MA, USA) water purification system. Nylon syringe filters 0.22 μm were from Millex-Hn (Mumbai, India). TLC plates used were obtained from Merck India Limited, Mumbai, India.
Instrumentation
CAMAG HPTLC system used for quantitative analysis consisted of 100 μl sample syringe (Hamilton, Switzerland), CAMAG Linomat V applicator (Camag, Switzerland), CAMAG glass twin-trough chambers (20 × 10 × 4 cm 3 ); TLC plate visualizing chamber and CAMAG TLC scanner III. Chromatographic data Equalization and instrument control were done using WinCATS software (V 1.4.2, CAMAG). The source of radiation was a deuterium lamp emitting a continuous UV spectrum in the range 190-400 nm.
Mobile Phase Preparation
The mobile phase was made of, n-hexane, ethyl acetate, glacial acetic acid (7:3:0.1 v/v/v)
Diluents Preparation
Dichloro methane used asdiluents.
Standard Preparation
Standard stock solution containing Orlistat 2000µg/mlwas prepared by taking 20.0mg Orlistat in 10 ml volumetric flask, 5ml of diluents (methylene dichloride) was added, sonicated and cooled to room temperature. The solution was diluted to the mark with diluents. Standard solution containing Orlistat (200 µg/ml) was prepared by pipetting 1 ml stock solution into a 10 ml volumetric flask and diluted up to the mark with diluents.
Chromatographic Conditions
Separation of Orlistat was carried out on silica gel 60F254, 10 × 10 cm 2 thin layer chromatography (TLC) plates with 6 mm band length and 10 µl injection volume. Development chamber was saturated for 30 min. prior. Ascending chromatography TLC plate developed using mobile phase containing nhexane, ethyl acetate, glacial acetic acid (7:3:0.1 v/v/v) respectively in glass twin-trough development chamber. The plates were developed up to a distance of 80 mm at temperature of 25°C and dried with hair drier at 50°C. Quantification was carried out with CAMAG TLC Scanner 3 operated by WinCats software using a deuterium lamp.
RESULTS AND DISCUSSION
Development and Optimization of the HPTLC Method
An analytical method based on TLC using densitometric detection was developed and validated for assay determination of Orlistat API. The analytical conditions were selected, keeping in mind the different chemical nature of Orlistat. The chemical and physical parameters e.g. solubility, pH, polar or nonpolar nature of the compound and peak wavelength. According to the literature review, the λ max values of were reported 190-220 nm. For the multi-component analysis of the drugs, most suitable wavelength was chosen; considering the maximum response were observed at 208 nm. The mobile phase selection has been done on the basis of resolution, Symmetry of peak, spot definition sensitivity and day-to-day reproducibility of the retardation factor and intensity or peak height and peak area Orlistat peaks. After evaluating all these factors, Nonpolar and polar solvent mixture was found to be giving satisfactory results. Initial trial was taken using methanol and chloroform as a mobile phase but we didn't get good peak shape (Trial 1, fig.2 ).
Figure2. Chromatogram of method development (Trial 1)
When chloroform was replaced by ethyl acetate the peak shape and little separationof drug was improved. (Trial 2, fig.3 ) After so many trial of method optimization, Orlistat was found suitable for faster development, resolution and peak shape of both components. Finally, the mobile phase composition consisted of a mixture of Hexane: Ethyl acetate: Glacial acetic acid (7.0:3.0:0.1 v/v/v). Optimized mobile phase proportion was providing good resolution between Orlistat. For the selection of polar organic constituent of mobile phase, Ethyl acetate was chosen to increase the retardation factor and to attain good peak shape with resolution. Figure (4 and 5) represents the chromatograms of standard and test preparation, respectively. The final optimized chromatographic conditions are given in the Table 1 . 
Figure4. Chromatogram of Orlistat standard preparation
Figure5. Chromatogram of Orlistat test preparation
Table1. Optimized chromatographic conditions for HPTLC
Parameters
Chromatographic Conditions
Method Validation
Solution Stability
Solution stability test was carried out by using sample and standard preparation stored at room temperature for 48 h. Sample and standard were stored without protection of light. The responses for the old solution were evaluated by comparison with freshly prepared standard solutions at the interval of 0 h, 12 h, 36 h, and 48 h. For the duration of the study of the stability of stored solutions assay was determined. At each interval solutions were applied on the plates; after development of plates, the chromatographs were evaluated for extra spots. There was no indication of compound instability in the sample solution was found through the study. Assay values acquired after 24 h and 36 h were statistically alike with the first value without measurable loss for Orlistat, respectively. Table 2 shows the summary of solution stability study. 
Specificity
Specificity is the measurement of the degree of interference from Impurity that may be expected to be present in the sample. Typically these might include impurities, degradation products, and diluents. The peak purity of bands for Orlistat in the sample was confirmed by comparing the R f values and spectra of the bands with standards. (Figure 6 ) It was assessed by comparing spectra at different levels, e. g. peak-start (S), peak-max (M) and peak-end (E) position of spots. There was no interference of any peakfromthese extraneous materials.
Figure6. Overlay UV spectra of Orlistat, standard and sample
Linearity
In a chromatographic method, linearity study was carried out preparing seven point calibration curve of concentration range from 80-320 µg/band (800-3200 ng/band) for Orlistat. The linearity assessed by test results which are directly proportional to the concentration of analyte which are present in the sample. (Table 3) The linear regression equation for Orlistat was y = 847.15x+3557.3 with correlation co-efficient 0.9984 Where x is the concentration in µg/ml and y is the peak area in absorbance unit.
The overlay chromatogram of all the levels of linearity is given in the figure 7 
LOD and LOQ
The limit of detection and limit of quantification were calculated using 3σ/S and 10σ/S equation for the developed method for LOD and LOQ, respectively. Where σ is the standard deviation of the yintercept and S is the slope of the calibration curve. For the LOD and LOQ study, concentrations were selected in the range of 800-3200 ng/band for Orlistat, respectively. The LOD value for Orlistat was found to be 1.14 µg/ml, and the LOQ value 3.81 µg/ml. The result shows the sensitivity of the methods
Accuracy
The accuracy study of an analytical procedure states the degree of closeness of agreement between the conventional true value or accepted reference value and the practically found value. Recovery of an ingredients was determined at three different concentration levels. The mean recovery for Orlistat was 99.13-99.92% .The satisfactory results indicating that the method was accurate and % recovery found within acceptance criteria.
Precision
The precision of the method, as repeatability was evaluated by performing six independent assays of the test sample preparation and calculating the SD, % RSD and mean % assay. The intermediate (inter-day) precision of the method was assessed by performing same procedure on different days by other analyst under the same experimental conditions with different make chemicals. The results obtain from the repeatability study was consider for the intra-day precision study also. The %RSD values for intermediate and method precision study was 0.017% and mean % assay was 99.79% as well as absolute difference between mean % assay values of method precision and intermediate precision found 0.04 % for Orlitat.
Robustness
The robustness study was evaluated with respect to the minute but a deliberate alteration in the chromatographic conditions, the result of the study delivers the reliability of the analysis. The change in Chromatographic parameters, e.g. composition of mobile phase, volume of mobile phase, chamber saturation time, detection wavelength. The effects of such deliberate changes on peak area and % assay were calculated, which found 99.60 % to 100.12 %. as well as % RSD for retardation factor found 0.67%.
System Suitability Study
Before measurement of validation parameter a system suitability test was performed by measurement of very important characteristics such as % RSD of peak area, % RSD of retardation factor observed and calculated for standard solutions. (Table 4 The experimental results obtained and calculated are suitable for the chromatographic method with inhouse limits.
CONCLUSION
A new analytical method was developed to be routinely applied to quantification of orlistat by a validated, simple and sensitive high performance thin layer chromatographic-densitometric assay method. Orlistat act as lipase inhibitor and prevents reducing of fate from human diet thus calorie intake is reduces. In this study, an analytical method based on TLC using densitometric detection was developed and validated for assay determination of Orlistat API. The developed procedure was evaluated for System suitability study, linearity, accuracy, precision, Robustness, LOD and LOQ. Hence, the method is recommended for routine quality control analysis of assay determination of Orlistat API.
